Jupiter Asset Management Ltd. Sells 83,055 Shares of Elanco Animal Health Incorporated $ELAN

Jupiter Asset Management Ltd. reduced its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 2.2% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 3,633,794 shares of the company’s stock after selling 83,055 shares during the period. Jupiter Asset Management Ltd.’s holdings in Elanco Animal Health were worth $82,233,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Elanco Animal Health during the first quarter valued at $2,065,000. Goldman Sachs Group Inc. lifted its stake in Elanco Animal Health by 104.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after purchasing an additional 2,445,872 shares in the last quarter. Empowered Funds LLC boosted its holdings in shares of Elanco Animal Health by 35.2% during the 1st quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock valued at $166,000 after purchasing an additional 4,121 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Elanco Animal Health by 4.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company’s stock valued at $18,830,000 after purchasing an additional 76,408 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its position in shares of Elanco Animal Health by 2,006.9% during the second quarter. Arrowstreet Capital Limited Partnership now owns 310,383 shares of the company’s stock valued at $4,432,000 after purchasing an additional 295,651 shares in the last quarter. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Trading Up 1.1%

ELAN opened at $23.94 on Friday. The stock has a 50-day moving average of $22.98 and a 200 day moving average of $23.32. The company has a current ratio of 2.16, a quick ratio of 1.12 and a debt-to-equity ratio of 0.60. Elanco Animal Health Incorporated has a 12 month low of $13.09 and a 12 month high of $27.72. The firm has a market cap of $11.96 billion, a P/E ratio of -47.88, a P/E/G ratio of 2.55 and a beta of 1.69.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.06. The business had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.28 billion. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The company’s revenue for the quarter was up 14.9% on a year-over-year basis. During the same period last year, the company earned $0.37 EPS. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. As a group, research analysts forecast that Elanco Animal Health Incorporated will post 1.11 EPS for the current year.

Analyst Upgrades and Downgrades

ELAN has been the topic of a number of research analyst reports. KeyCorp boosted their target price on Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Leerink Partners raised their price target on Elanco Animal Health from $26.00 to $30.00 and gave the company an “outperform” rating in a report on Tuesday, February 24th. Weiss Ratings cut Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 11th. Morgan Stanley increased their target price on Elanco Animal Health from $22.00 to $24.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 25th. Finally, JPMorgan Chase & Co. raised their target price on shares of Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $28.20.

Insiders Place Their Bets

In other news, insider Rajeev A. Modi bought 4,911 shares of Elanco Animal Health stock in a transaction dated Friday, May 15th. The shares were acquired at an average price of $20.35 per share, with a total value of $99,938.85. Following the completion of the purchase, the insider owned 160,812 shares in the company, valued at $3,272,524.20. The trade was a 3.15% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Jeffrey N. Simmons bought 4,971 shares of the stock in a transaction dated Friday, May 15th. The stock was purchased at an average price of $20.09 per share, with a total value of $99,867.39. Following the acquisition, the chief executive officer directly owned 171,971 shares in the company, valued at approximately $3,454,897.39. The trade was a 2.98% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 1.14% of the stock is owned by company insiders.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.